nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K2—melanoma	0.392	0.569	CbGaD
Trametinib—MAP2K1—melanoma	0.297	0.431	CbGaD
Trametinib—CYP3A4—Temozolomide—melanoma	0.0245	0.576	CbGbCtD
Trametinib—CYP3A4—Vemurafenib—melanoma	0.0134	0.316	CbGbCtD
Trametinib—CYP3A4—Docetaxel—melanoma	0.00461	0.108	CbGbCtD
Trametinib—Neoplasm—Carmustine—melanoma	0.000364	0.00332	CcSEcCtD
Trametinib—Dry eye—Temozolomide—melanoma	0.000359	0.00327	CcSEcCtD
Trametinib—Eye disorder—Vemurafenib—melanoma	0.000357	0.00325	CcSEcCtD
Trametinib—Cardiac disorder—Vemurafenib—melanoma	0.000355	0.00323	CcSEcCtD
Trametinib—Neoplasm—Temozolomide—melanoma	0.000352	0.0032	CcSEcCtD
Trametinib—Angiopathy—Vemurafenib—melanoma	0.000347	0.00316	CcSEcCtD
Trametinib—Mediastinal disorder—Vemurafenib—melanoma	0.000344	0.00314	CcSEcCtD
Trametinib—Chills—Vemurafenib—melanoma	0.000343	0.00312	CcSEcCtD
Trametinib—Rash erythematous—Docetaxel—melanoma	0.000338	0.00308	CcSEcCtD
Trametinib—Malnutrition—Vemurafenib—melanoma	0.000333	0.00303	CcSEcCtD
Trametinib—Erythema—Vemurafenib—melanoma	0.000333	0.00303	CcSEcCtD
Trametinib—Dysgeusia—Vemurafenib—melanoma	0.000326	0.00297	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.000325	0.00296	CcSEcCtD
Trametinib—Back pain—Vemurafenib—melanoma	0.000322	0.00293	CcSEcCtD
Trametinib—MAP2K1—neck—melanoma	0.000308	0.207	CbGeAlD
Trametinib—Hyponatraemia—Carmustine—melanoma	0.000293	0.00267	CcSEcCtD
Trametinib—Cough—Vemurafenib—melanoma	0.00029	0.00265	CcSEcCtD
Trametinib—Bone disorder—Docetaxel—melanoma	0.000286	0.00261	CcSEcCtD
Trametinib—Oropharyngeal pain—Docetaxel—melanoma	0.000284	0.00259	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Docetaxel—melanoma	0.000284	0.00259	CcSEcCtD
Trametinib—Arthralgia—Vemurafenib—melanoma	0.000283	0.00258	CcSEcCtD
Trametinib—Myalgia—Vemurafenib—melanoma	0.000283	0.00258	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000281	0.00256	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000281	0.00256	CcSEcCtD
Trametinib—Infection—Vemurafenib—melanoma	0.00027	0.00246	CcSEcCtD
Trametinib—Nervous system disorder—Vemurafenib—melanoma	0.000266	0.00243	CcSEcCtD
Trametinib—Hypokalaemia—Carmustine—melanoma	0.000266	0.00242	CcSEcCtD
Trametinib—Skin disorder—Vemurafenib—melanoma	0.000264	0.0024	CcSEcCtD
Trametinib—Dehydration—Temozolomide—melanoma	0.000263	0.00239	CcSEcCtD
Trametinib—Dry skin—Temozolomide—melanoma	0.000259	0.00236	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Docetaxel—melanoma	0.000259	0.00236	CcSEcCtD
Trametinib—Hypokalaemia—Temozolomide—melanoma	0.000257	0.00234	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000254	0.00232	CcSEcCtD
Trametinib—Neutropenia—Dactinomycin—melanoma	0.000252	0.0023	CcSEcCtD
Trametinib—Stomatitis—Bleomycin—melanoma	0.000251	0.00229	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000249	0.00227	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000247	0.00225	CcSEcCtD
Trametinib—Haematuria—Bleomycin—melanoma	0.000246	0.00224	CcSEcCtD
Trametinib—Neutropenia—Carmustine—melanoma	0.000236	0.00215	CcSEcCtD
Trametinib—Decreased appetite—Vemurafenib—melanoma	0.000236	0.00215	CcSEcCtD
Trametinib—Stomatitis—Dactinomycin—melanoma	0.000234	0.00214	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000234	0.00214	CcSEcCtD
Trametinib—Fatigue—Vemurafenib—melanoma	0.000234	0.00213	CcSEcCtD
Trametinib—Neoplasm—Docetaxel—melanoma	0.000234	0.00213	CcSEcCtD
Trametinib—Haemoglobin—Bleomycin—melanoma	0.000233	0.00212	CcSEcCtD
Trametinib—Constipation—Vemurafenib—melanoma	0.000232	0.00212	CcSEcCtD
Trametinib—Haemorrhage—Bleomycin—melanoma	0.000232	0.00211	CcSEcCtD
Trametinib—MAP2K1—eye—melanoma	0.000229	0.154	CbGeAlD
Trametinib—Neutropenia—Temozolomide—melanoma	0.000228	0.00208	CcSEcCtD
Trametinib—Hyperglycaemia—Carmustine—melanoma	0.000228	0.00208	CcSEcCtD
Trametinib—Renal failure—Carmustine—melanoma	0.000221	0.00202	CcSEcCtD
Trametinib—Hyperglycaemia—Temozolomide—melanoma	0.00022	0.00201	CcSEcCtD
Trametinib—Stomatitis—Carmustine—melanoma	0.000219	0.002	CcSEcCtD
Trametinib—Urinary tract infection—Carmustine—melanoma	0.000219	0.00199	CcSEcCtD
Trametinib—Infestation NOS—Temozolomide—melanoma	0.000218	0.00198	CcSEcCtD
Trametinib—Infestation—Temozolomide—melanoma	0.000218	0.00198	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000216	0.00197	CcSEcCtD
Trametinib—Body temperature increased—Vemurafenib—melanoma	0.000215	0.00196	CcSEcCtD
Trametinib—Stomatitis—Temozolomide—melanoma	0.000212	0.00193	CcSEcCtD
Trametinib—Urinary tract infection—Temozolomide—melanoma	0.000211	0.00193	CcSEcCtD
Trametinib—Chills—Bleomycin—melanoma	0.000208	0.00189	CcSEcCtD
Trametinib—Cardiac failure congestive—Docetaxel—melanoma	0.000207	0.00189	CcSEcCtD
Trametinib—Haemoglobin—Carmustine—melanoma	0.000203	0.00185	CcSEcCtD
Trametinib—Haemorrhage—Carmustine—melanoma	0.000202	0.00184	CcSEcCtD
Trametinib—Erythema—Bleomycin—melanoma	0.000202	0.00184	CcSEcCtD
Trametinib—MAP2K1—skin of body—melanoma	0.000199	0.134	CbGeAlD
Trametinib—Oedema peripheral—Carmustine—melanoma	0.000199	0.00181	CcSEcCtD
Trametinib—Connective tissue disorder—Carmustine—melanoma	0.000199	0.00181	CcSEcCtD
Trametinib—Haemoglobin—Temozolomide—melanoma	0.000196	0.00179	CcSEcCtD
Trametinib—Haemorrhage—Temozolomide—melanoma	0.000195	0.00178	CcSEcCtD
Trametinib—Asthenia—Vemurafenib—melanoma	0.000195	0.00178	CcSEcCtD
Trametinib—Chills—Dactinomycin—melanoma	0.000194	0.00177	CcSEcCtD
Trametinib—Urinary tract disorder—Temozolomide—melanoma	0.000193	0.00176	CcSEcCtD
Trametinib—Oedema peripheral—Temozolomide—melanoma	0.000192	0.00175	CcSEcCtD
Trametinib—Pruritus—Vemurafenib—melanoma	0.000192	0.00175	CcSEcCtD
Trametinib—Connective tissue disorder—Temozolomide—melanoma	0.000192	0.00175	CcSEcCtD
Trametinib—Urethral disorder—Temozolomide—melanoma	0.000191	0.00174	CcSEcCtD
Trametinib—Eye disorder—Carmustine—melanoma	0.000189	0.00172	CcSEcCtD
Trametinib—Hyponatraemia—Docetaxel—melanoma	0.000188	0.00172	CcSEcCtD
Trametinib—Erythema—Dactinomycin—melanoma	0.000188	0.00171	CcSEcCtD
Trametinib—Pain in extremity—Docetaxel—melanoma	0.000188	0.00171	CcSEcCtD
Trametinib—Anaemia—Bleomycin—melanoma	0.000186	0.0017	CcSEcCtD
Trametinib—Diarrhoea—Vemurafenib—melanoma	0.000186	0.00169	CcSEcCtD
Trametinib—Eye disorder—Temozolomide—melanoma	0.000183	0.00166	CcSEcCtD
Trametinib—Cardiac disorder—Temozolomide—melanoma	0.000181	0.00165	CcSEcCtD
Trametinib—Arrhythmia—Carmustine—melanoma	0.000181	0.00165	CcSEcCtD
Trametinib—Leukopenia—Bleomycin—melanoma	0.00018	0.00164	CcSEcCtD
Trametinib—Dizziness—Vemurafenib—melanoma	0.00018	0.00164	CcSEcCtD
Trametinib—Angiopathy—Temozolomide—melanoma	0.000177	0.00161	CcSEcCtD
Trametinib—Mental disorder—Carmustine—melanoma	0.000177	0.00161	CcSEcCtD
Trametinib—Mediastinal disorder—Temozolomide—melanoma	0.000176	0.0016	CcSEcCtD
Trametinib—Malnutrition—Carmustine—melanoma	0.000176	0.0016	CcSEcCtD
Trametinib—Erythema—Carmustine—melanoma	0.000176	0.0016	CcSEcCtD
Trametinib—Cough—Bleomycin—melanoma	0.000176	0.0016	CcSEcCtD
Trametinib—MAP2K2—skin of body—melanoma	0.000175	0.118	CbGeAlD
Trametinib—Chills—Temozolomide—melanoma	0.000175	0.0016	CcSEcCtD
Trametinib—Dehydration—Docetaxel—melanoma	0.000175	0.00159	CcSEcCtD
Trametinib—Anaemia—Dactinomycin—melanoma	0.000174	0.00158	CcSEcCtD
Trametinib—Vomiting—Vemurafenib—melanoma	0.000173	0.00157	CcSEcCtD
Trametinib—Dry skin—Docetaxel—melanoma	0.000172	0.00157	CcSEcCtD
Trametinib—Myalgia—Bleomycin—melanoma	0.000172	0.00156	CcSEcCtD
Trametinib—Abdominal pain upper—Docetaxel—melanoma	0.000171	0.00156	CcSEcCtD
Trametinib—Rash—Vemurafenib—melanoma	0.000171	0.00156	CcSEcCtD
Trametinib—Mental disorder—Temozolomide—melanoma	0.000171	0.00156	CcSEcCtD
Trametinib—Dermatitis—Vemurafenib—melanoma	0.000171	0.00156	CcSEcCtD
Trametinib—Back pain—Carmustine—melanoma	0.00017	0.00155	CcSEcCtD
Trametinib—Headache—Vemurafenib—melanoma	0.00017	0.00155	CcSEcCtD
Trametinib—Erythema—Temozolomide—melanoma	0.00017	0.00155	CcSEcCtD
Trametinib—Malnutrition—Temozolomide—melanoma	0.00017	0.00155	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000169	0.00154	CcSEcCtD
Trametinib—Leukopenia—Dactinomycin—melanoma	0.000168	0.00153	CcSEcCtD
Trametinib—Dysgeusia—Temozolomide—melanoma	0.000166	0.00152	CcSEcCtD
Trametinib—Vision blurred—Carmustine—melanoma	0.000166	0.00151	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000166	0.00151	CcSEcCtD
Trametinib—Oedema—Bleomycin—melanoma	0.000164	0.0015	CcSEcCtD
Trametinib—Back pain—Temozolomide—melanoma	0.000164	0.0015	CcSEcCtD
Trametinib—Infection—Bleomycin—melanoma	0.000163	0.00149	CcSEcCtD
Trametinib—Anaemia—Carmustine—melanoma	0.000163	0.00148	CcSEcCtD
Trametinib—Nausea—Vemurafenib—melanoma	0.000161	0.00147	CcSEcCtD
Trametinib—Thrombocytopenia—Bleomycin—melanoma	0.000161	0.00147	CcSEcCtD
Trametinib—Vision blurred—Temozolomide—melanoma	0.00016	0.00146	CcSEcCtD
Trametinib—MAP2K2—mammalian vulva—melanoma	0.00016	0.108	CbGeAlD
Trametinib—Myalgia—Dactinomycin—melanoma	0.00016	0.00146	CcSEcCtD
Trametinib—Leukopenia—Carmustine—melanoma	0.000157	0.00144	CcSEcCtD
Trametinib—Anaemia—Temozolomide—melanoma	0.000157	0.00143	CcSEcCtD
Trametinib—Oedema—Dactinomycin—melanoma	0.000153	0.0014	CcSEcCtD
Trametinib—Infection—Dactinomycin—melanoma	0.000152	0.00139	CcSEcCtD
Trametinib—Leukopenia—Temozolomide—melanoma	0.000152	0.00139	CcSEcCtD
Trametinib—Hypertension—Carmustine—melanoma	0.000152	0.00138	CcSEcCtD
Trametinib—Neutropenia—Docetaxel—melanoma	0.000152	0.00138	CcSEcCtD
Trametinib—Thrombocytopenia—Dactinomycin—melanoma	0.00015	0.00137	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Bleomycin—melanoma	0.00015	0.00137	CcSEcCtD
Trametinib—Myalgia—Carmustine—melanoma	0.00015	0.00136	CcSEcCtD
Trametinib—Cough—Temozolomide—melanoma	0.000148	0.00135	CcSEcCtD
Trametinib—Hypertension—Temozolomide—melanoma	0.000147	0.00134	CcSEcCtD
Trametinib—Myalgia—Temozolomide—melanoma	0.000145	0.00132	CcSEcCtD
Trametinib—Arthralgia—Temozolomide—melanoma	0.000145	0.00132	CcSEcCtD
Trametinib—Infestation NOS—Docetaxel—melanoma	0.000145	0.00132	CcSEcCtD
Trametinib—Infestation—Docetaxel—melanoma	0.000145	0.00132	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000144	0.00131	CcSEcCtD
Trametinib—Oedema—Carmustine—melanoma	0.000144	0.00131	CcSEcCtD
Trametinib—Decreased appetite—Bleomycin—melanoma	0.000143	0.0013	CcSEcCtD
Trametinib—Infection—Carmustine—melanoma	0.000143	0.0013	CcSEcCtD
Trametinib—Renal failure—Docetaxel—melanoma	0.000142	0.0013	CcSEcCtD
Trametinib—Dry mouth—Temozolomide—melanoma	0.000142	0.00129	CcSEcCtD
Trametinib—Stomatitis—Docetaxel—melanoma	0.000141	0.00129	CcSEcCtD
Trametinib—Thrombocytopenia—Carmustine—melanoma	0.000141	0.00128	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00014	0.00127	CcSEcCtD
Trametinib—Oedema—Temozolomide—melanoma	0.000139	0.00126	CcSEcCtD
Trametinib—Infection—Temozolomide—melanoma	0.000138	0.00126	CcSEcCtD
Trametinib—Epistaxis—Docetaxel—melanoma	0.000136	0.00124	CcSEcCtD
Trametinib—Nervous system disorder—Temozolomide—melanoma	0.000136	0.00124	CcSEcCtD
Trametinib—Thrombocytopenia—Temozolomide—melanoma	0.000136	0.00124	CcSEcCtD
Trametinib—Skin disorder—Temozolomide—melanoma	0.000135	0.00123	CcSEcCtD
Trametinib—Hyperhidrosis—Temozolomide—melanoma	0.000134	0.00122	CcSEcCtD
Trametinib—Decreased appetite—Dactinomycin—melanoma	0.000133	0.00122	CcSEcCtD
Trametinib—Fatigue—Dactinomycin—melanoma	0.000132	0.00121	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Carmustine—melanoma	0.000131	0.00119	CcSEcCtD
Trametinib—Haemoglobin—Docetaxel—melanoma	0.000131	0.00119	CcSEcCtD
Trametinib—MAP2K1—head—melanoma	0.00013	0.0874	CbGeAlD
Trametinib—Body temperature increased—Bleomycin—melanoma	0.00013	0.00118	CcSEcCtD
Trametinib—Haemorrhage—Docetaxel—melanoma	0.00013	0.00118	CcSEcCtD
Trametinib—Insomnia—Carmustine—melanoma	0.00013	0.00118	CcSEcCtD
Trametinib—Urinary tract disorder—Docetaxel—melanoma	0.000128	0.00117	CcSEcCtD
Trametinib—Oedema peripheral—Docetaxel—melanoma	0.000128	0.00117	CcSEcCtD
Trametinib—Connective tissue disorder—Docetaxel—melanoma	0.000128	0.00116	CcSEcCtD
Trametinib—Urethral disorder—Docetaxel—melanoma	0.000127	0.00116	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000126	0.00115	CcSEcCtD
Trametinib—Insomnia—Temozolomide—melanoma	0.000125	0.00114	CcSEcCtD
Trametinib—Gastrointestinal pain—Dactinomycin—melanoma	0.000125	0.00114	CcSEcCtD
Trametinib—Decreased appetite—Carmustine—melanoma	0.000125	0.00114	CcSEcCtD
Trametinib—Gastrointestinal disorder—Carmustine—melanoma	0.000124	0.00113	CcSEcCtD
Trametinib—Constipation—Carmustine—melanoma	0.000123	0.00112	CcSEcCtD
Trametinib—Eye disorder—Docetaxel—melanoma	0.000121	0.00111	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—melanoma	0.000121	0.00111	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—melanoma	0.000121	0.00111	CcSEcCtD
Trametinib—Decreased appetite—Temozolomide—melanoma	0.000121	0.0011	CcSEcCtD
Trametinib—Cardiac disorder—Docetaxel—melanoma	0.000121	0.0011	CcSEcCtD
Trametinib—Gastrointestinal disorder—Temozolomide—melanoma	0.00012	0.00109	CcSEcCtD
Trametinib—Fatigue—Temozolomide—melanoma	0.00012	0.00109	CcSEcCtD
Trametinib—Constipation—Temozolomide—melanoma	0.000119	0.00108	CcSEcCtD
Trametinib—Asthenia—Bleomycin—melanoma	0.000118	0.00108	CcSEcCtD
Trametinib—Angiopathy—Docetaxel—melanoma	0.000118	0.00107	CcSEcCtD
Trametinib—Gastrointestinal pain—Carmustine—melanoma	0.000117	0.00107	CcSEcCtD
Trametinib—Mediastinal disorder—Docetaxel—melanoma	0.000117	0.00107	CcSEcCtD
Trametinib—Chills—Docetaxel—melanoma	0.000117	0.00106	CcSEcCtD
Trametinib—Pruritus—Bleomycin—melanoma	0.000116	0.00106	CcSEcCtD
Trametinib—Arrhythmia—Docetaxel—melanoma	0.000116	0.00106	CcSEcCtD
Trametinib—MAP2K2—head—melanoma	0.000115	0.077	CbGeAlD
Trametinib—Mental disorder—Docetaxel—melanoma	0.000114	0.00104	CcSEcCtD
Trametinib—Body temperature increased—Carmustine—melanoma	0.000114	0.00103	CcSEcCtD
Trametinib—Abdominal pain—Carmustine—melanoma	0.000114	0.00103	CcSEcCtD
Trametinib—Gastrointestinal pain—Temozolomide—melanoma	0.000113	0.00103	CcSEcCtD
Trametinib—Malnutrition—Docetaxel—melanoma	0.000113	0.00103	CcSEcCtD
Trametinib—Erythema—Docetaxel—melanoma	0.000113	0.00103	CcSEcCtD
Trametinib—Dysgeusia—Docetaxel—melanoma	0.000111	0.00101	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—melanoma	0.00011	0.001	CcSEcCtD
Trametinib—Abdominal pain—Temozolomide—melanoma	0.00011	0.001	CcSEcCtD
Trametinib—Body temperature increased—Temozolomide—melanoma	0.00011	0.001	CcSEcCtD
Trametinib—Back pain—Docetaxel—melanoma	0.000109	0.000997	CcSEcCtD
Trametinib—Muscle spasms—Docetaxel—melanoma	0.000109	0.000991	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—melanoma	0.000105	0.000956	CcSEcCtD
Trametinib—Vomiting—Bleomycin—melanoma	0.000105	0.000953	CcSEcCtD
Trametinib—Anaemia—Docetaxel—melanoma	0.000104	0.000952	CcSEcCtD
Trametinib—Rash—Bleomycin—melanoma	0.000104	0.000945	CcSEcCtD
Trametinib—Dermatitis—Bleomycin—melanoma	0.000104	0.000944	CcSEcCtD
Trametinib—Asthenia—Carmustine—melanoma	0.000103	0.000939	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—melanoma	0.000101	0.000922	CcSEcCtD
Trametinib—Asthenia—Temozolomide—melanoma	9.95e-05	0.000907	CcSEcCtD
Trametinib—Cough—Docetaxel—melanoma	9.87e-05	0.000899	CcSEcCtD
Trametinib—Diarrhoea—Carmustine—melanoma	9.82e-05	0.000895	CcSEcCtD
Trametinib—Pruritus—Temozolomide—melanoma	9.82e-05	0.000895	CcSEcCtD
Trametinib—Nausea—Bleomycin—melanoma	9.77e-05	0.00089	CcSEcCtD
Trametinib—Hypertension—Docetaxel—melanoma	9.76e-05	0.00089	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—melanoma	9.75e-05	0.000889	CcSEcCtD
Trametinib—Rash—Dactinomycin—melanoma	9.67e-05	0.000881	CcSEcCtD
Trametinib—Myalgia—Docetaxel—melanoma	9.63e-05	0.000877	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—melanoma	9.63e-05	0.000877	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	9.56e-05	0.000871	CcSEcCtD
Trametinib—Dizziness—Carmustine—melanoma	9.49e-05	0.000865	CcSEcCtD
Trametinib—Diarrhoea—Temozolomide—melanoma	9.49e-05	0.000865	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—melanoma	9.41e-05	0.000858	CcSEcCtD
Trametinib—Oedema—Docetaxel—melanoma	9.23e-05	0.000841	CcSEcCtD
Trametinib—Dizziness—Temozolomide—melanoma	9.18e-05	0.000836	CcSEcCtD
Trametinib—Infection—Docetaxel—melanoma	9.17e-05	0.000835	CcSEcCtD
Trametinib—Vomiting—Carmustine—melanoma	9.13e-05	0.000832	CcSEcCtD
Trametinib—Nausea—Dactinomycin—melanoma	9.11e-05	0.00083	CcSEcCtD
Trametinib—MAP2K1—lymph node—melanoma	9.11e-05	0.0612	CbGeAlD
Trametinib—Rash—Carmustine—melanoma	9.05e-05	0.000825	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—melanoma	9.05e-05	0.000825	CcSEcCtD
Trametinib—Dermatitis—Carmustine—melanoma	9.04e-05	0.000824	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—melanoma	9.03e-05	0.000823	CcSEcCtD
Trametinib—Headache—Carmustine—melanoma	8.99e-05	0.00082	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—melanoma	8.96e-05	0.000817	CcSEcCtD
Trametinib—Vomiting—Temozolomide—melanoma	8.82e-05	0.000804	CcSEcCtD
Trametinib—Rash—Temozolomide—melanoma	8.75e-05	0.000797	CcSEcCtD
Trametinib—Dermatitis—Temozolomide—melanoma	8.74e-05	0.000796	CcSEcCtD
Trametinib—Headache—Temozolomide—melanoma	8.69e-05	0.000792	CcSEcCtD
Trametinib—Nausea—Carmustine—melanoma	8.53e-05	0.000777	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—melanoma	8.41e-05	0.000766	CcSEcCtD
Trametinib—Insomnia—Docetaxel—melanoma	8.35e-05	0.000761	CcSEcCtD
Trametinib—Nausea—Temozolomide—melanoma	8.24e-05	0.000751	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—melanoma	8.02e-05	0.000731	CcSEcCtD
Trametinib—MAP2K2—lymph node—melanoma	8.02e-05	0.0539	CbGeAlD
Trametinib—Gastrointestinal disorder—Docetaxel—melanoma	7.97e-05	0.000726	CcSEcCtD
Trametinib—Fatigue—Docetaxel—melanoma	7.96e-05	0.000725	CcSEcCtD
Trametinib—Constipation—Docetaxel—melanoma	7.89e-05	0.000719	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—melanoma	7.55e-05	0.000688	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—melanoma	7.29e-05	0.000665	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—melanoma	7.29e-05	0.000665	CcSEcCtD
Trametinib—Asthenia—Docetaxel—melanoma	6.62e-05	0.000603	CcSEcCtD
Trametinib—Pruritus—Docetaxel—melanoma	6.53e-05	0.000595	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—melanoma	6.31e-05	0.000575	CcSEcCtD
Trametinib—Dizziness—Docetaxel—melanoma	6.1e-05	0.000556	CcSEcCtD
Trametinib—Vomiting—Docetaxel—melanoma	5.87e-05	0.000535	CcSEcCtD
Trametinib—Rash—Docetaxel—melanoma	5.82e-05	0.00053	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—melanoma	5.81e-05	0.00053	CcSEcCtD
Trametinib—Headache—Docetaxel—melanoma	5.78e-05	0.000527	CcSEcCtD
Trametinib—Nausea—Docetaxel—melanoma	5.48e-05	0.000499	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—RAC1—melanoma	3.88e-06	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—melanoma	3.88e-06	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CD—melanoma	3.85e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SPP1—melanoma	3.84e-06	2.43e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTAP—melanoma	3.84e-06	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAP2K2—melanoma	3.83e-06	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—melanoma	3.82e-06	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—melanoma	3.82e-06	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—melanoma	3.81e-06	2.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2—melanoma	3.79e-06	2.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—melanoma	3.76e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—melanoma	3.76e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—melanoma	3.76e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MDM2—melanoma	3.74e-06	2.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—melanoma	3.72e-06	2.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP17A1—melanoma	3.69e-06	2.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MDM2—melanoma	3.69e-06	2.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGF2—melanoma	3.69e-06	2.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—melanoma	3.68e-06	2.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—melanoma	3.65e-06	2.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1B—melanoma	3.65e-06	2.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.64e-06	2.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—melanoma	3.64e-06	2.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—melanoma	3.64e-06	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—melanoma	3.64e-06	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAC1—melanoma	3.63e-06	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—melanoma	3.63e-06	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—melanoma	3.6e-06	2.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	3.6e-06	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—melanoma	3.59e-06	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—melanoma	3.58e-06	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—melanoma	3.57e-06	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—melanoma	3.56e-06	2.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—melanoma	3.55e-06	2.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—melanoma	3.52e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—melanoma	3.52e-06	2.23e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNA11—melanoma	3.49e-06	2.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—melanoma	3.48e-06	2.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—melanoma	3.45e-06	2.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—melanoma	3.45e-06	2.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FN1—melanoma	3.43e-06	2.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LUM—melanoma	3.42e-06	2.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PHGDH—melanoma	3.42e-06	2.17e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—FASN—melanoma	3.41e-06	2.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—melanoma	3.41e-06	2.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—melanoma	3.4e-06	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—melanoma	3.37e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—melanoma	3.37e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—melanoma	3.37e-06	2.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—melanoma	3.36e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—melanoma	3.36e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—melanoma	3.36e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—melanoma	3.35e-06	2.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPSE—melanoma	3.35e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—melanoma	3.35e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NFKB1—melanoma	3.34e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—melanoma	3.34e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—melanoma	3.33e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—melanoma	3.33e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—melanoma	3.32e-06	2.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CUBN—melanoma	3.29e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD80—melanoma	3.28e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—melanoma	3.28e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—melanoma	3.28e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—melanoma	3.28e-06	2.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—melanoma	3.28e-06	2.08e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNAQ—melanoma	3.24e-06	2.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CD44—melanoma	3.24e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—melanoma	3.24e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—melanoma	3.22e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FN1—melanoma	3.21e-06	2.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—melanoma	3.18e-06	2.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SDHD—melanoma	3.18e-06	2.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CSPG4—melanoma	3.18e-06	2.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BSG—melanoma	3.18e-06	2.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.18e-06	2.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—melanoma	3.15e-06	2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—melanoma	3.15e-06	1.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.15e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—melanoma	3.14e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—melanoma	3.14e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—melanoma	3.14e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NFKB1—melanoma	3.13e-06	1.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1B1—melanoma	3.11e-06	1.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—melanoma	3.11e-06	1.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—melanoma	3.11e-06	1.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—melanoma	3.1e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—melanoma	3.08e-06	1.95e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPAM—melanoma	3.08e-06	1.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD80—melanoma	3.07e-06	1.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—melanoma	3.07e-06	1.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—melanoma	3.07e-06	1.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—melanoma	3.07e-06	1.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—melanoma	3.07e-06	1.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—melanoma	3.03e-06	1.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—melanoma	3e-06	1.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—melanoma	3e-06	1.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—melanoma	3e-06	1.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK1—melanoma	2.99e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—melanoma	2.99e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—melanoma	2.98e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—melanoma	2.94e-06	1.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—melanoma	2.91e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAP2K1—melanoma	2.9e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—melanoma	2.9e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—melanoma	2.88e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—melanoma	2.88e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—melanoma	2.87e-06	1.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—melanoma	2.82e-06	1.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—melanoma	2.81e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—melanoma	2.81e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—melanoma	2.8e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK1—melanoma	2.8e-06	1.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—melanoma	2.79e-06	1.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—melanoma	2.77e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—melanoma	2.77e-06	1.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGF2—melanoma	2.76e-06	1.75e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.74e-06	1.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK1—melanoma	2.73e-06	1.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—melanoma	2.73e-06	1.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—melanoma	2.7e-06	1.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—melanoma	2.68e-06	1.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—melanoma	2.65e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—melanoma	2.64e-06	1.67e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLA2G6—melanoma	2.62e-06	1.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—melanoma	2.59e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—melanoma	2.59e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—melanoma	2.59e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—melanoma	2.58e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGF2—melanoma	2.58e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—melanoma	2.58e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—melanoma	2.58e-06	1.63e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—melanoma	2.56e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK1—melanoma	2.55e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—melanoma	2.55e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—melanoma	2.55e-06	1.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK1—melanoma	2.52e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—melanoma	2.52e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—melanoma	2.51e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—melanoma	2.48e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—melanoma	2.43e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—melanoma	2.42e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—melanoma	2.41e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—melanoma	2.41e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—melanoma	2.41e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—melanoma	2.4e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—melanoma	2.38e-06	1.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—melanoma	2.38e-06	1.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—melanoma	2.37e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK1—melanoma	2.36e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—melanoma	2.36e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—melanoma	2.36e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PRKCA—melanoma	2.36e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—VCAN—melanoma	2.35e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—melanoma	2.35e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ERCC2—melanoma	2.34e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—melanoma	2.31e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—melanoma	2.31e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—melanoma	2.3e-06	1.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—melanoma	2.26e-06	1.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—melanoma	2.25e-06	1.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—melanoma	2.24e-06	1.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—melanoma	2.23e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—melanoma	2.23e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—melanoma	2.22e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—melanoma	2.21e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—melanoma	2.19e-06	1.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—melanoma	2.19e-06	1.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—melanoma	2.18e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—melanoma	2.18e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—melanoma	2.17e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—melanoma	2.16e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKB1—melanoma	2.16e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—melanoma	2.16e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—melanoma	2.15e-06	1.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—melanoma	2.12e-06	1.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—melanoma	2.1e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—melanoma	2.1e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—melanoma	2.08e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—melanoma	2.05e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—melanoma	2.05e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—melanoma	2.04e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—melanoma	2.04e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—melanoma	2.03e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—melanoma	2.02e-06	1.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKB1—melanoma	2.02e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP17A1—melanoma	1.98e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—melanoma	1.98e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—melanoma	1.96e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—melanoma	1.96e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—melanoma	1.94e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—melanoma	1.94e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—melanoma	1.94e-06	1.23e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.94e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—melanoma	1.94e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—melanoma	1.89e-06	1.2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNA11—melanoma	1.87e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—melanoma	1.85e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—melanoma	1.85e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—melanoma	1.83e-06	1.16e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FASN—melanoma	1.83e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—melanoma	1.82e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—melanoma	1.81e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—melanoma	1.81e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—melanoma	1.81e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—melanoma	1.8e-06	1.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—melanoma	1.8e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—melanoma	1.79e-06	1.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—melanoma	1.78e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK1—melanoma	1.77e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—melanoma	1.76e-06	1.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNAQ—melanoma	1.74e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CD44—melanoma	1.74e-06	1.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—melanoma	1.74e-06	1.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—melanoma	1.69e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—melanoma	1.67e-06	1.06e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1B1—melanoma	1.67e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—melanoma	1.67e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK1—melanoma	1.65e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—melanoma	1.65e-06	1.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—melanoma	1.62e-06	1.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—melanoma	1.6e-06	1.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—melanoma	1.56e-06	9.88e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—melanoma	1.53e-06	9.7e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—melanoma	1.48e-06	9.39e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—melanoma	1.43e-06	9.08e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—melanoma	1.42e-06	8.98e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—melanoma	1.41e-06	8.96e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—melanoma	1.4e-06	8.88e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—melanoma	1.39e-06	8.78e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—melanoma	1.37e-06	8.71e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—melanoma	1.36e-06	8.59e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—melanoma	1.33e-06	8.4e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—melanoma	1.27e-06	8.04e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PRKCA—melanoma	1.27e-06	8.01e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ERCC2—melanoma	1.25e-06	7.95e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—melanoma	1.25e-06	7.93e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—melanoma	1.22e-06	7.74e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—melanoma	1.17e-06	7.42e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—melanoma	9.91e-07	6.28e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—melanoma	9.56e-07	6.06e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—melanoma	8.71e-07	5.52e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—melanoma	8.62e-07	5.46e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—melanoma	8.6e-07	5.45e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—melanoma	7.59e-07	4.81e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—melanoma	7.52e-07	4.77e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—melanoma	7.04e-07	4.46e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—melanoma	6.56e-07	4.16e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—melanoma	4.63e-07	2.93e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—melanoma	3.78e-07	2.4e-06	CbGpPWpGaD
